[toc]

- [Summaries](#summaries)
  - [Table 1. Virus Variants and Spike Mutations vs Monoclonal Antibodies](#table.1.virus.variants.and.spike.mutations.vs.monoclonal.antibodies)
  - [Table 2. Variants of Concern, Variants of Interest, and Other Variants for which Neutralization Data are Available](#table.2.variants.of.concern.variants.of.interest.and.other.variants.for.which.neutralization.data.are.available)
  - [Table 3. Individual SARS-CoV-2 Spike Mutations for which Data are Available](#table.3.individual.sars-cov-2.spike.mutations.for.which.data.are.available)
  - [Table 4. Monoclonal Antibodies (mAbs) with Emergency Use Authorization (EUA) or in Advanced Clinical Trials](#table.4.monoclonal.antibodies.mabs.with.emergency.use.authorization.eua.or.in.advanced.clinical.trials)
  - [Table 5. Numbers of Vaccinee Plasma (VP) Neutralization Experiments According to the Vaccine, History of Previous Infection, Time Since Infection, and SARS-CoV-2 Variant Tested](#table.5.numbers.of.vaccinee.plasma.vp.neutralization.experiments.according.to.the.vaccine.history.of.previous.infection.time.since.infection.and.sars-cov-2.variant.tested)
  - [Table 6. Numbers of Convalescent Plasma (CP) Neutralization Experiments According to the Infecting Virus, Time Since Infection, and SARS-CoV-2 Variant Tested](#table.6.numbers.of.convalescent.plasma.cp.neutralization.experiments.according.to.the.infecting.virus.time.since.infection.and.sars-cov-2.variant.tested)
  <!-- - [Document 1] -->
  - [Figure 1: Distribution of fold-reduction in susceptibilities (A) and of absolute neutralizing titers (B) of vaccinee plasma (VP) associated with eight vaccines to the five variants of concern (VOC)](#figure.1.distribution.of.fold-reduction.in.susceptibilities.a.and.of.absolute.neutralizing.titers.b.of.vaccinee.plasma.vp.associated.with.eight.vaccines.to.the.five.variants.of.concern.voc.)
  - [Figure 2: Monoclonal antibodies (mAbs) with EUAs or in advanced clinical development: receptor binding domain (RBD) epitopes and immune escape positions.](#figure.2.monoclonal.antibodies.mabs.with.euas.or.in.advanced.clinical.development.receptor.binding.domain.rbd.epitopes.and.immune.escape.positions.)

  - [Table 7. Virus Variants and Spike Mutations vs Convalescent Plasma](#table.7.virus.variants.and.spike.mutations.vs.convalescent.plasma)
  - [Table 8. Virus Variants and Spike Mutations vs Plasma from Vaccinated Persons](#table.8.virus.variants.and.spike.mutations.vs.plasma.from.vaccinated.persons)
  - [Table 9. Omicron Spike Mutations vs Monoclonal Antibodies](#table.9.omicron.spike.mutations.vs.monoclonal.antibodies)
  - [Table 10. Omicron Spike Mutations DMS Score](#table.10.omicron.spike.mutations.dms.score)

- Lookup tables
  - [mAb (monoclonal antibody) synonyms](/page/mab-synonyms)
  - [Wildtype mutations](/page/wildtype)
- [References](#references)

[/toc]

## Summaries

### Table 1. Virus Variants and Spike Mutations vs Monoclonal Antibodies

#### Fold reduced neutralizing susceptibility to monoclonal antibodies under Emergency Use Authorization (EUA)

[table compact, lastCompact]
table_mab
[/table]

#### Fold reduced neutralizing susceptibility to monoclonal antibodies in other clinical trials

[table compact,lastCompact]
table_mab_non_eua
[/table]

- The fold reduction in susceptibility is the median value of results, the subscript is the number of samples. “-” indicates absence of susceptibility data.
- Spike mutations:
  - **Alpha, B.1.1.7**: HV69-70∆, ∆144, N501Y, A570D, D614G, P681H, T716I, S982A, and D1118H.
  - **Beta, B.1.351**: L18F, D80A, D215G, ∆242-244, R246I, K417N, E484K, N501Y, D614G, and A701V.
  - **Gamma, P.1**: L18F, T20N, P26S, D138Y, R190S, K417T, E484K, N501Y, D614G, H655Y, T1027I, and V1176F.
  - **Delta, B.1.617.2**: T19R, FR157-158∆, L452R, T478K, D614G, P681R, D950N.
  - **Iota, B.1.526**: L5F, T95I, D253G, E484K, D614G, A701V.
  - **Epsilon, B.1.427/9**: S13I, W152C, L452R, D614G.
  - **Kappa, B.1.617.1**: T95I, L452R, E484Q, D614G, P681R, Q1071H.
  - **Omicron/BA.1**: A67V, HV69-70∆, T95I, G142D, VYY143-145∆, N211∆, L212I, R214EPEins, G339D, S371L, S373P, S375F, K417N, N440K, G446S, S477N, T478K, E484A, Q493R, G496S, Q498R, N501Y, Y505H, T547K, H655Y, N679K, P681H, N764K, D796Y, N856K, Q954H, N969K, L981F
  - **Omicron/BA.2**: T19I, L24S, PPA25-27∆, G142D, V213G, G339D, S371F, S373P, S375F, T376A, D405N, R408S, K417N, N440K, S477N, T478K, E484A, Q493R, Q498R, N501Y, Y505H, D614G, H655Y, N679K, P681H, N764K, D796Y, Q954H, N969K
  - **Omicron/BA.4**: T19I, L24S, PPA25-27∆, HV69-70∆, G142D, V213G, G339D, S371F, S373P, S375F, T376A, D405N, R408S, K417N, N440K, L452R, S477N, T478K, E484A, F486V, Q498R, N501Y, Y505H, D614G, H655Y, N679K, P681H, N764K, D796Y, Q954H, N969K
  - **Omicron/BA.5**: T19I, L24S, PPA25-27∆, HV69-70∆, G142D, V213G, G339D, S371F, S373P, S375F, T376A, D405N, R408S, K417N, N440K, L452R, S477N, T478K, E484A, F486V, Q498R, N501Y, Y505H, D614G, H655Y, N679K, P681H, N764K, D796Y, Q954H, N969K
  - **Omicron/BA.2.12.1**: T19I, L24S, PPA25-27∆, G142D, V213G, G339D, S371F, S373P, S375F, T376A, D405N, R408S, K417N, N440K, L452R, S477N, T478K, E484A, Q493R, Q498R, N501Y, Y505H, D614G, H655Y, N679K, P681H, N764K, D796Y, Q954H, N969K
- Monoclonal antibody(mAb) abbreviations:
  **BAM**: Bamlanivimab/LY-CoV555/LY3819253,
  **ETE**: Etesevimab/LY-CoV016/JS016/CB6,
  **CAS**: Casirivimab/REGN10933,
  **IMD**: Imdevimab/REGN10987,
  **CIL**: Cilgavimab/COV2-2130/AZD1061,
  **TIX**: Tixagevimab/COV2-2196/AZD8895,
  **SOT**: Sotrovimab/Vir-7831/S309,
  **BEB**: Bebtelovimab/LY-CoV1404/LY3853113,
  **REG**: Regdanvimab/CT-P59,
  **AMU**: Amubarvimab/BRII-196/P2C-1f11,
  **ROM**: Romlusevimab/BRII-198/P2B-1G5,
  **ADI**: Adintrevimab/ADG20/ADG-2.
- The color scheme indicates the fold-reduction in neutralization: <span style="padding: .1rem .2rem; margin: 0 .2rem; border: 1px solid black; background-color: #ffffff; color: black;">absence of color</span> – &lt;5-fold reduced susceptibility; <span style="padding: .1rem .2rem; margin: 0 .2rem; border: 1px solid black; background-color: #7fcbee; color: black;">light blue</span> – 5 to 24.9-fold reduced susceptibility; <span style="padding: .1rem .2rem; margin: 0 .2rem; border: 1px solid black; background-color: #146aa8; color: white;">dark blue</span> – ≥25-fold reduced susceptibility.


***


### Table 2. Variants of Concern, Variants of Interest, and Other Variants for which Neutralization Data are Available

[table compact,lastCompact]
table_variants
[/table]

<!-- #### Variants of concern

[table compact,lastCompact]
table_variants_of_concern
[/table]

#### Variants of interest

[table compact,lastCompact]
table_variants_of_interest
[/table]

#### Other variants containing >=1 RBD mutation

[table compact,lastCompact]
table_variants_other_rbd
[/table] -->


***


### Table 3. Individual SARS-CoV-2 Spike Mutations for which Data are Available

[table compact,lastCompact]
table_single_mut
[/table]

<!-- #### Receptor-binding domain (RBD)

[table compact,lastCompact]
table_mut_rbd
[/table]

#### N-terminal domain (NTD)

[table compact,lastCompact]
table_mut_ntd
[/table]

#### C-terminal domain of S1 (CTD)

[table compact,lastCompact]
table_mut_ctd
[/table]

#### S2

[table compact,lastCompact]
table_mut_s2
[/table] -->

***


### Table 4. Monoclonal Antibodies (mAbs) with Emergency Use Authorization (EUA) or in Advanced Clinical Trials

[table compact,lastCompact]
table_mab_detail
[/table]

RBM (receptor binding motif) is the part of the receptor binding domain (RBD) that contains the spike ACE2 binding residues. RBM class 1 mAbs bind epitopes dominated by ACE2-binding residues and as a result bind solely when the RBD is in the up/open position. RBM class 2 mAbs have a smaller ACE2-binding footprint and can often bind the RBD in down/closed position. RBD core mAbs target a surface accessible part of the RBD that is separate from the RBM. 2The publications and results include those describing both in vitro selection and neutralization experiments.


***


### Table 5. Numbers of Vaccinee Plasma (VP) Neutralization Experiments According to the Vaccine, History of Previous Infection, Time Since Infection, and SARS-CoV-2 Variant Tested

#### Vaccine

[table compact,lastCompact]
table_vp_vaccine
[/table]

<!-- #### Previously SARS-CoV-2 infected

[table compact,lastCompact]
table_vp_infection
[/table] -->

#### Time since vaccination

[table compact,lastCompact]
table_vp_time
[/table]

#### Variant / mutations undergoing neutralization

[table compact,lastCompact]
table_vp_variant
[/table]

<!-- #### Number of vaccinations

[table compact,lastCompact]
table_vp_dosage
[/table] -->


The numbers of references and results obtained from persons receiving uncommonly studied vaccines or vaccine combinations are not shown.

***


### Table 6. Numbers of Convalescent Plasma (CP) Neutralization Experiments According to the Infecting Virus, Time Since Infection, and SARS-CoV-2 Variant Tested

#### Infecting virus

[table compact,lastCompact]
table_cp_infection
[/table]

#### Time since infection

[table compact,lastCompact]
table_cp_time
[/table]

#### Variant / mutations undergoing neutralization

[table compact,lastCompact]
table_cp_variant
[/table]

***


### Figure 1: Distribution of fold-reduction in susceptibilities (A) and of absolute neutralizing titers (B) of vaccinee plasma (VP) associated with eight vaccines to the five variants of concern (VOC)

<div class="figure-image">

![fold titer 1 month](susceptibility-data/fold-titer.png#!maxHeight=35rem&marginLeft=0)


The X axes indicate the Greek letter associated with each VOC. The Y axes indicate the number of neutralizing assays. The numbers above the stacked bars indicate the number of studies reporting the experimental results. The figure includes VP obtained solely from previously uninfected persons receiving a complete vaccination schedule.

</div>

***

### Figure 2: Monoclonal antibodies (mAbs) with EUAs or in advanced clinical development: receptor binding domain (RBD) epitopes and immune escape positions.

<div class="figure-image">

![mab](susceptibility-data/mab.png#!maxHeight=50rem&marginLeft=0)


For each mAb, the top of the RBD and two side views are depicted using coordinates from PDB 6M0J. ACE2 binding residues are shown in red; the mAb epitope defined as those residues within 4.5 angstroms of the RBD is shown in dark blue; and ACE2 binding residues within the mAb epitope are shown in purple. Those positions containing mutations that were either selected by the mAb in vitro (“SEL”), reduced binding in a deep mutational scanning assay (“DMS”), and/or reduced in vitro neutralizing susceptibility by a median of ≥4-fold in CoV-RDB (drug resistance; “DR”) are also indicated. The mAb epitopes for BAM (bamlanivimab), ETE (etesevimab), CAS (casirivimab), IMD (imdevimab), SOT (sotrovirmab), BEB (Bebtelovimab), CIL (cilgavimab) and TIX (tixagevimab) were determined from their PDB structures.

</div>



### Table 7. Virus Variants and Spike Mutations vs Convalescent Plasma

[table compact,lastCompact]
table_cp
[/table]

- Convalescent plasma in all studies is presumed likely to have been obtained from persons infected with spike variants lacking mutations associated with reduced neutralization susceptibility.

***


### Table 8. Virus Variants and Spike Mutations vs Plasma from Vaccinated Persons

[table compact,lastCompact]
table_vp
[/table]


***



### Table 9. Omicron Spike Mutations vs Monoclonal Antibodies

#### Fold reduced neutralizing susceptibility to monoclonal antibodies under Emergency Use Authorization (EUA)

[table compact, lastCompact]
table_omicron_mab
[/table]

#### Fold reduced neutralizing susceptibility to monoclonal antibodies in other clinical trials

[table compact,lastCompact]
table_omicron_mab_non_eua
[/table]


***


### Table 10. Omicron Spike Mutations DMS Score

[table compact,lastCompact]
table_omicron_dms
[/table]

- Escape scores are from [jbloomlab/SARS2_RBD_Ab_escape_maps](https://github.com/jbloomlab/SARS2_RBD_Ab_escape_maps)

***


<section>

<div class="figure-caption">

## References

- **Abe21**: [^Abe21#inline]
- **Acevedo21**: [^Acevedo21#inline]
- **Aggarwal21**: [^Aggarwal21#inline]
- **Ai21**: [^Ai21#inline]
- **Alenquer21**: [^Alenquer21#inline]
- **Alter21**: [^Alter21#inline]
- **Andrade21**: [^Andrade21#inline]
- **Andreano21**: [^Andreano21#inline]
- **Anichini21**: [^Anichini21#inline]
- **Annavajhala21b**: [^Annavajhala21b#inline]
- **Arien21**: [^Arien21#inline]
- **Arora21**: [^Arora21#inline]
- **Arora21b**: [^Arora21b#inline]
- **Arunachalam21**: [^Arunachalam21#inline]
- **Assawakosri22**: [^Assawakosri22#inline]
- **AstraZenica21c**: [^AstraZenica21c#inline]
- **Barouch21**: [^Barouch21#inline]
- **Barros-Martins21**: [^Barros-Martins21#inline]
- **Basile21**: [^Basile21#inline]
- **Bates21**: [^Bates21#inline]
- **Bates21b**: [^Bates21b#inline]
- **Baum20**: [^Baum20#inline]
- **Becker21**: [^Becker21#inline]
- **Behrens21**: [^Behrens21#inline]
- **Bekliz21**: [^Bekliz21#inline]
- **Betton21**: [^Betton21#inline]
- **Boschi22**: [^Boschi22#inline]
- **Brii21**: [^Brii21#inline]
- **Brown21**: [^Brown21#inline]
- **Cameroni21**: [^Cameroni21#inline]
- **Caniels21**: [^Caniels21#inline]
- **Cantoni21**: [^Cantoni21#inline]
- **Cao21**: [^Cao21#inline]
- **Cao22**: [^Cao22#inline]
- **Carreno21**: [^Carreno21#inline]
- **Carreno21b**: [^Carreno21b#inline]
- **Cathcart21**: [^Cathcart21#inline]
- **Cele21**: [^Cele21#inline]
- **Cele21c**: [^Cele21c#inline]
- **Cele22**: [^Cele22#inline]
- **Changrob21**: [^Changrob21#inline]
- **Chen21**: [^Chen21#inline]
- **Chen21c**: [^Chen21c#inline]
- **Chen21d**: [^Chen21d#inline]
- **Chen22**: [^Chen22#inline]
- **Cho21**: [^Cho21#inline]
- **Choi21**: [^Choi21#inline]
- **Choi21b**: [^Choi21b#inline]
- **Collier21**: [^Collier21#inline]
- **Collier21b**: [^Collier21b#inline]
- **Copin21**: [^Copin21#inline]
- **Corbett21**: [^Corbett21#inline]
- **Cui22**: [^Cui22#inline]
- **Debes22**: [^Debes22#inline]
- **Dejnirattisai21**: [^Dejnirattisai21#inline]
- **Dejnirattisai21b**: [^Dejnirattisai21b#inline]
- **Dejnirattisai22**: [^Dejnirattisai22#inline]
- **Deng21**: [^Deng21#inline]
- **Diez21**: [^Diez21#inline]
- **Dolzhikova21**: [^Dolzhikova21#inline]
- **Dong21**: [^Dong21#inline]
- **Doria-Rose21**: [^Doria-Rose21#inline]
- **Drews21**: [^Drews21#inline]
- **Du20**: [^Du20#inline]
- **Du21**: [^Du21#inline]
- **Dupont21**: [^Dupont21#inline]
- **Duty22**: [^Duty22#inline]
- **Edara21**: [^Edara21#inline]
- **Edara21b**: [^Edara21b#inline]
- **Edara21c**: [^Edara21c#inline]
- **Edara21d**: [^Edara21d#inline]
- **Emary21**: [^Emary21#inline]
- **FDA21**: [^FDA21#inline]
- **FDA21c**: [^FDA21c#inline]
- **Fabricius21**: [^Fabricius21#inline]
- **Falsey21**: [^Falsey21#inline]
- **Faulkner21**: [^Faulkner21#inline]
- **Fenwick21**: [^Fenwick21#inline]
- **Fernandez21**: [^Fernandez21#inline]
- **Ferreira21**: [^Ferreira21#inline]
- **Francino-Urdaniz21**: [^Francino-Urdaniz21#inline]
- **Gaebler22**: [^Gaebler22#inline]
- **Garcia-Beltran21**: [^Garcia-Beltran21#inline]
- **Garcia-Beltran22**: [^Garcia-Beltran22#inline]
- **Geers21**: [^Geers21#inline]
- **Gidari21**: [^Gidari21#inline]
- **Goel21**: [^Goel21#inline]
- **Goel21b**: [^Goel21b#inline]
- **Gong21**: [^Gong21#inline]
- **Gottlieb21**: [^Gottlieb21#inline]
- **Graham21**: [^Graham21#inline]
- **Greaney20**: [^Greaney20#inline]
- **Greaney21**: [^Greaney21#inline]
- **Greaney21c**: [^Greaney21c#inline]
- **Greaney21d**: [^Greaney21d#inline]
- **Gross21**: [^Gross21#inline]
- **Gruell22**: [^Gruell22#inline]
- **Gushchin21**: [^Gushchin21#inline]
- **Hadjadj21**: [^Hadjadj21#inline]
- **Haslwanter21**: [^Haslwanter21#inline]
- **Haveri21**: [^Haveri21#inline]
- **Haveri21b**: [^Haveri21b#inline]
- **Hayashi21**: [^Hayashi21#inline]
- **Hoffmann21**: [^Hoffmann21#inline]
- **Hoffmann21b**: [^Hoffmann21b#inline]
- **Hoffmann21c**: [^Hoffmann21c#inline]
- **Hoffmann22**: [^Hoffmann22#inline]
- **Hu21**: [^Hu21#inline]
- **Hu21c**: [^Hu21c#inline]
- **Hu21d**: [^Hu21d#inline]
- **Huang21b**: [^Huang21b#inline]
- **Ikegame21**: [^Ikegame21#inline]
- **Ikemura21**: [^Ikemura21#inline]
- **Iketani22**: [^Iketani22#inline]
- **Imai21**: [^Imai21#inline]
- **Jacobsen21**: [^Jacobsen21#inline]
- **Jalkanen21**: [^Jalkanen21#inline]
- **Jangra21**: [^Jangra21#inline]
- **Jongeneelen21**: [^Jongeneelen21#inline]
- **Ju22**: [^Ju22#inline]
- **Kant21**: [^Kant21#inline]
- **Keeton21**: [^Keeton21#inline]
- **Kemp21**: [^Kemp21#inline]
- **Khan21**: [^Khan21#inline]
- **Kimura21**: [^Kimura21#inline]
- **Kitchin21**: [^Kitchin21#inline]
- **Kumar21**: [^Kumar21#inline]
- **Kuzmina21**: [^Kuzmina21#inline]
- **Lapa22**: [^Lapa22#inline]
- **Lassauniere21**: [^Lassauniere21#inline]
- **Lechmere21**: [^Lechmere21#inline]
- **Ledesma21**: [^Ledesma21#inline]
- **Leier21**: [^Leier21#inline]
- **Li20h**: [^Li20h#inline]
- **Li21c**: [^Li21c#inline]
- **Li21d**: [^Li21d#inline]
- **Lien21**: [^Lien21#inline]
- **Liu21**: [^Liu21#inline]
- **Liu21b**: [^Liu21b#inline]
- **Liu21d**: [^Liu21d#inline]
- **Liu21e**: [^Liu21e#inline]
- **Liu21f**: [^Liu21f#inline]
- **Liu21g**: [^Liu21g#inline]
- **Liu21h**: [^Liu21h#inline]
- **Liu21k**: [^Liu21k#inline]
- **Liu21l**: [^Liu21l#inline]
- **Lu21b**: [^Lu21b#inline]
- **Lucas21**: [^Lucas21#inline]
- **Luke21**: [^Luke21#inline]
- **Lustig21**: [^Lustig21#inline]
- **Lusvarghi22**: [^Lusvarghi22#inline]
- **Ma21**: [^Ma21#inline]
- **Madhi21**: [^Madhi21#inline]
- **Makdasi21**: [^Makdasi21#inline]
- **Mallm21**: [^Mallm21#inline]
- **Margolis21**: [^Margolis21#inline]
- **Marot21**: [^Marot21#inline]
- **McCallum21b**: [^McCallum21b#inline]
- **McCallum21c**: [^McCallum21c#inline]
- **Medigeshi22**: [^Medigeshi22#inline]
- **Meng22**: [^Meng22#inline]
- **Messali21**: [^Messali21#inline]
- **Mishra21**: [^Mishra21#inline]
- **Miyakawa21**: [^Miyakawa21#inline]
- **Miyakawa21b**: [^Miyakawa21b#inline]
- **Miyamoto21**: [^Miyamoto21#inline]
- **Mlcochova21**: [^Mlcochova21#inline]
- **Monin21**: [^Monin21#inline]
- **Moore21**: [^Moore21#inline]
- **Moriyama21**: [^Moriyama21#inline]
- **Moyo-Gwete21**: [^Moyo-Gwete21#inline]
- **Muecksch21**: [^Muecksch21#inline]
- **Muecksch21b**: [^Muecksch21b#inline]
- **Muecksch22**: [^Muecksch22#inline]
- **Muik21**: [^Muik21#inline]
- **Muik21b**: [^Muik21b#inline]
- **Muller21**: [^Muller21#inline]
- **Nabel21**: [^Nabel21#inline]
- **Nadesalingam21**: [^Nadesalingam21#inline]
- **Neerukonda21**: [^Neerukonda21#inline]
- **Nemet21**: [^Nemet21#inline]
- **Neumann21**: [^Neumann21#inline]
- **Newman21**: [^Newman21#inline]
- **Nguyen21**: [^Nguyen21#inline]
- **Nguyen21b**: [^Nguyen21b#inline]
- **Pannus21**: [^Pannus21#inline]
- **Parry21**: [^Parry21#inline]
- **Payne21**: [^Payne21#inline]
- **Pegu21**: [^Pegu21#inline]
- **Planas21**: [^Planas21#inline]
- **Planas21b**: [^Planas21b#inline]
- **Planas21c**: [^Planas21c#inline]
- **Rees-Spear21**: [^Rees-Spear21#inline]
- **Reincke21**: [^Reincke21#inline]
- **Ren21**: [^Ren21#inline]
- **Reynolds21**: [^Reynolds21#inline]
- **Riou21**: [^Riou21#inline]
- **Roessler21**: [^Roessler21#inline]
- **Rondinone21**: [^Rondinone21#inline]
- **Rothenberger21**: [^Rothenberger21#inline]
- **Ryu21**: [^Ryu21#inline]
- **Ryu21b**: [^Ryu21b#inline]
- **Saade21**: [^Saade21#inline]
- **Sahin20**: [^Sahin20#inline]
- **Sahin21**: [^Sahin21#inline]
- **Sapkal21**: [^Sapkal21#inline]
- **Sapkal21b**: [^Sapkal21b#inline]
- **Sapkal21c**: [^Sapkal21c#inline]
- **Scheid21**: [^Scheid21#inline]
- **Schmidt21**: [^Schmidt21#inline]
- **Schmidt21b**: [^Schmidt21b#inline]
- **Schmitz21**: [^Schmitz21#inline]
- **Shen21**: [^Shen21#inline]
- **Shen21b**: [^Shen21b#inline]
- **Sheward22**: [^Sheward22#inline]
- **Skelly21**: [^Skelly21#inline]
- **Spencer21**: [^Spencer21#inline]
- **Stadtmuller21**: [^Stadtmuller21#inline]
- **Stamatatos21**: [^Stamatatos21#inline]
- **Stankov21**: [^Stankov21#inline]
- **Starr21**: [^Starr21#inline]
- **Supasa21**: [^Supasa21#inline]
- **Suthar21**: [^Suthar21#inline]
- **Syed21**: [^Syed21#inline]
- **Tada21**: [^Tada21#inline]
- **Tada21c**: [^Tada21c#inline]
- **Tada21d**: [^Tada21d#inline]
- **Tada21e**: [^Tada21e#inline]
- **Tada22**: [^Tada22#inline]
- **Takashita22**: [^Takashita22#inline]
- **Takashita22b**: [^Takashita22b#inline]
- **Tang21**: [^Tang21#inline]
- **Tea21**: [^Tea21#inline]
- **Thomson21**: [^Thomson21#inline]
- **Torres21**: [^Torres21#inline]
- **Tortorici20**: [^Tortorici20#inline]
- **Touret22**: [^Touret22#inline]
- **Trinite21**: [^Trinite21#inline]
- **Trombetta21**: [^Trombetta21#inline]
- **Turner21**: [^Turner21#inline]
- **Uriu21**: [^Uriu21#inline]
- **Uriu22**: [^Uriu22#inline]
- **Vacharathit21**: [^Vacharathit21#inline]
- **Valleriani21**: [^Valleriani21#inline]
- **VanBlargan22**: [^VanBlargan22#inline]
- **Vanhove21**: [^Vanhove21#inline]
- **Vicenti21**: [^Vicenti21#inline]
- **Vidal21**: [^Vidal21#inline]
- **Virtanen21**: [^Virtanen21#inline]
- **Wall21**: [^Wall21#inline]
- **Wall21b**: [^Wall21b#inline]
- **Wang21**: [^Wang21#inline]
- **Wang21b**: [^Wang21b#inline]
- **Wang21d**: [^Wang21d#inline]
- **Wang21e**: [^Wang21e#inline]
- **Wang21f**: [^Wang21f#inline]
- **Wang21g**: [^Wang21g#inline]
- **Wang21i**: [^Wang21i#inline]
- **Wang21j**: [^Wang21j#inline]
- **Wang22**: [^Wang22#inline]
- **Wang22b**: [^Wang22b#inline]
- **Weigang21**: [^Weigang21#inline]
- **Weisblum20**: [^Weisblum20#inline]
- **West21**: [^West21#inline]
- **Westendorf21**: [^Westendorf21#inline]
- **Wibmer21**: [^Wibmer21#inline]
- **Widera21**: [^Widera21#inline]
- **Wilhelm21**: [^Wilhelm21#inline]
- **Wilhelm21b**: [^Wilhelm21b#inline]
- **Wilson21**: [^Wilson21#inline]
- **Wu21**: [^Wu21#inline]
- **Wu21c**: [^Wu21c#inline]
- **Xie21**: [^Xie21#inline]
- **Xie21b**: [^Xie21b#inline]
- **Yadav21**: [^Yadav21#inline]
- **Yadav21b**: [^Yadav21b#inline]
- **Yadav21c**: [^Yadav21c#inline]
- **Yadav21d**: [^Yadav21d#inline]
- **Yamasoba22**: [^Yamasoba22#inline]
- **Yao21**: [^Yao21#inline]
- **Yi21**: [^Yi21#inline]
- **Yu21b**: [^Yu21b#inline]
- **Yu21c**: [^Yu21c#inline]
- **Yu22**: [^Yu22#inline]
- **Yuan21**: [^Yuan21#inline]
- **Yuan22**: [^Yuan22#inline]
- **Zani21**: [^Zani21#inline]
- **Zeng21**: [^Zeng21#inline]
- **Zeng21b**: [^Zeng21b#inline]
- **Zhang21c**: [^Zhang21c#inline]
- **Zhang21f**: [^Zhang21f#inline]
- **Zhang21g**: [^Zhang21g#inline]
- **Zhao21**: [^Zhao21#inline]
- **Zhou21b**: [^Zhou21b#inline]
- **Zhou21c**: [^Zhou21c#inline]
- **Zhou21e**: [^Zhou21e#inline]
- **Zhou22**: [^Zhou22#inline]
- **Zou21**: [^Zou21#inline]
- **Zou21b**: [^Zou21b#inline]
- **Zuckerman21**: [^Zuckerman21#inline]
- **Zuckerman21b**: [^Zuckerman21b#inline]
- **deSouza21**: [^deSouza21#inline]

</div>

</section>
